•H emophiliaisachronic andexpensive condition, with antihemophilicfactormedications accountingfor up to 93% of totalmedical cost,depending on severity.
•H IV andHCV coinfectionhas been associated with increased morbidity, mortality,and clottingfactorutilization in hemophiliapatients.
•T his is thefirst studyofhemophiliaand coinfectionwithHIV and/or HCVinaU.S commerciallyinsured population andthe firsttoidentifythe sourcesand magnitudeofcomponenthealth care costs.
•C ompared with themeanannualizedcost in 2004 dollars for patients with H-only ($90,942,median=$63,613), HIV + HCV coinfectionwas associated with 59%greater costs( $144,462, median=$111,542, P =0.005).
•T he health care services thatcontributed to greatertotal costs forhemophiliapatientscoinfected with both HCVand HIV than forpatientswithhemophiliaonlyincluded antihemophilic (clottingfactor) medication,outpatientcosts, prescription drugs other than antihemophilicmedications,and hospital inpatient costs.
What is alreadyknownaboutthissubject
What this studyadds Medical Costs andResource Utilization for HemophiliaPatientsWith andWithoutHI VorHCV Infection B yt he early1 980s,m ost hemophiliap atientsh ad been exposedt ot he hepatitisBvirusf romp lasma-derived factor VIII concentrates usedf or theirt reatment. 1 At that time,h epatitis wasc onsideredamanageable risk giventhe benefitso fh emophiliat reatment.H owever, theh epatitis Cv irus (HCV)was still uncharacterized,and despitethe introduction of viralinactivationtechniquesinthe mid-1980s, by theend of the decade most hemophiliap atientsw ereu nknowingly infected. 2 In addition,t he emergenceo ft he humani mmunodeficiency virus( HIV) in thee arly 1980ss everely affected theh emophilia population,mainlythroughcontaminated blood products. 3 It has been estimated thato ft he approximately 15,500 hemophiliacs in theU nited States,a bout 9,465( 61%) were infected with HIV before theprotectivebenefit of heat-treated factor VIII waswidely knowna nd accepted. 1 With thei ntroductiono fh igh-purity plasma-derived factor concentrates in thelate1 980s andrecombinant products in theearly 1990s,the possibility of contracting HIVo rH CV has been virtuallye liminated;h owever,a pproximatelyo ne thirdo fh emophiliacsi nt he United States between theagesof2 1and60years areHIV infected,and 80%are HCV infected. 4 Mortalityf roml iver disease in hemophiliad ue to HCVi s almost 17 timesh ighert hani nt he generalp opulationa nd is 6times higher forliver cancer. 5 HIVhas been showntoaccelerate instanceso fH CV-related cirrhosis andl iver failure, particularly whenhemophiliaispresent. 6, 7 Telfer et al.found that,onaverage, 15 yearsafter initialexposuretofactorconcentrates,hemophilic patients coinfected with HIVand HCVwere21times more likely to developd ecompensated liverf ailuret hanw ereH CV monoinfected patients. 8 However, theeffect of HCVonHIV progression has notb eenf ully established. Whiles omes tudies have found that HCVc oinfectiond oesn ot affect HIVp rogression, 9 other studiesh ave foundt hatH IV progresses faster in thep resence of HCV. 10, 11 Thep resenceo fb idirectionali nterferencesb etween HIVa nd HCVhave complicated thetreatment of coinfected individuals. 12 Frequentd rugi nteractions,u niquet oxicities, andag reater likelihood of adverse events associated with antiviralt herapy have been observed in coinfected individuals. 13 Partly because of theh ighp revalenceo fH CV coinfectioni nH IV patients, liverd iseasei st he leadingc ause of deathi nH IV-infected individuals.
14 Af ew studiesh ave reported thee ffect of HIVi nfectiono n resource utilization in hemophiliacs. WhileG lobe at al.d id not findas tatistically significantassociation betweenHIV positivity andt he number of hospitalizationso rt he number of inpatient hospital days,M inerse ta l. foundt hatH IV-positiveh emophilia patients were more likelyt ohave outpatienth ospitalvisitsthan were hemophiliap atientsw ho were HIVn egative. 15, 16 Moreover, in hemophiliap atientsi nfected with HIV, ad ecreasei nC D4+ counts has been associated with an increase in clottingf actor utilization,withend-stage AIDS hemophiliapatientsconsuming upward of 50%m orec lottingf actort hanw hent heya re asymptomatic. 17 Hemophilia is ac hronic ande xpensive condition,w ith antihemophilicm edications accountingf or 45%-93%o ft otal health care costs, dependingonseverity andtreatment regimen. [18] [19] [20] In patients with inhibitors to factor VIII,c lottingf actorc oncentrates accountf or up to 99%o ft otal costs. 21 Bohn et al.f ound that that thec ost of hemophiliar angedf rom$ 30,820 pery ear forp atientst reated on demand to $87,865f or patients treated on prophylaxis, 19 whileastudy by Globeetal. estimated that the overall annual cost of hemophiliacareinCaliforniawas $139,102 in 1995. 18 Thes tudy foundt hath ighert otal health care costs were correlated with HIVseropositivity,arthropathy,and inhibitors to factor VIII.I na ddition, they foundt hatH IV infection wasa ssociatedwiths ignificantly higher factor use.M olho et al. foundthatthe mean annual treatment cost of patients with severe hemophilia, of whom 94.8%wereH CV positive and5 5.2% HIV positive,was US$73,029inFrancein1 998. 22 Thes lowr esponset oa ct on thee mergingH IV contamination of theb lood supplyl ed to devastatingc onsequencesf or patients with hemophilia. 1 This wasd ue in part to thecostsand difficultya ssociatedw itht he developmenta nd administration of appropriateinterventions to protect theb lood supply,suchas screeningand viralinactivation. 23 Poor vigilance of theemerging HIVand HCVthreatresultedinahigh rate of infectionand consequentlyimposed afinancial burden on health care payers and patients.Heemstraetal. foundthatwhile theannualizedcost of hemophiliac aref or 17 boys treated between1 978 and1 998i n aT oronto children's hospital wasCan$27,409f or severe patients with no viralt ransmission,i tw as approximatelyC an$85,448 forp atientsm ono-infected with HIVa nd Can$111,809 for patients coinfected with HIVa nd hepatitisBo rC . 24 Costsw ere underestimated because thes tudy didn ot report drug costs relatedt oH IV andH CV.F ew others tudies have attemptedt o quantifythe economic impactofHIV and/or HCVcoinfectionin hemophiliap atients. Thep urpose of this studyi st od etermine theh ealth care resource utilization of adulth emophiliap atients with andwithout HIVand HCVinfectioninthe UnitedStates. andpharmacyclaimsdata, includingNationalDrugCode(NDC) numbers, quantity,and days supply.Additionaldataelementsin thea dministratived atabasei nclude provider specialty, member eligibility,d ateo fs ervice,a nd plan cost.P lanc ost is defined as thenet plan cost aftersubtraction of membercost-share.
■■ Methods

Data
PatientSelectionCriteria
Patientsf or this studyw eres elected if they were continuously enrolled fora tl east 6m onths, were >18y ears of age, andm ale ( Figure) .H emophiliap atientsw erei dentifiedu sing ICD-9-CM, HCPCS, andN DC numbers. In an effort to overcome possible coding errors,hemophiliapatientswereidentifiedifthey( 1) had at least1m edical claim with ap rimary diagnosiso fh emophilia (ICD-9-CMc odes 286.XX), (2)w erem ale( to excludec ases of vonW illebrand disease), and( 3) hada tl east 1p harmacyo r medicalclaim forahemophiliadrugidentifiedbyNDC numbers (Table 1) andJcodes: J7190-J7199, Q0187orQ2022.
PatientshavinginhibitorstofactorVIII or factor IX,identified throught he dispensation of recombinant factor VIIa (rFVIIa), NovoSeven, or activatedp rothrombin complexc oncentrate (APCC),F EIBA VH,w eree xcludedf romt he study. Virally infected patients were identified as thoseh emophiliap atients with at least1medical claim with an HIVdiagnosis (ICD-9-CM codes042.xx, 079.53)orHCV infection(ICD-9-CM codes070.41, 070.44,0 70.51, 070.54)i nt he primary, secondary, or tertiary diagnosesf ields. Four patientc ohortsw eree stablished:h emophiliaw ithout coinfectionf rome itherH IV or HCV( H-only); hemophilia + HIV( H + HIV);h emophilia + HCV( H + HCV);a nd
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hemophilia + HIV + HCV( H + HIV + HCV).T he indexd atew as defined as thef irst dayo fe nrollmentand follow-upl astedu ntil theend of thepatient's enrollmentorthe endofthe studyperiod. Because of thelimitations of theclaimsdata, it wasonlyknown whether at estw as orderedf or ap articularp atient. Neithert he laboratory test resultsn or hemophilias everity wasa vailable for theanalysis. Thestudy protocol wasa pprovedbythe University of Southern California InstitutionalReviewBoard.
OutcomesMeasures
Twomaino utcomesweremeasuredfromJanuary1 997through
April2 004: (1)c ost (net plan cost afters ubtraction of member cost-share)a ssociatedw itha ll pharmacy andm edical claims and( 2) number of office visits overall andbyphysician specialty during thes tudy.Costsw ereannualizedb yc omputingthe sum of totalc ostsf or each patienta nd dividing by thet otal numbero fp atient months of eligibility multiplied by 12.M edical expenditures were adjusted to 2004 dollarsu sing them edical consumer pricei ndexa nd were subdivided into outpatient, hospital inpatient, emergencyr oom, antihemophilicm edication, andn on-hemophiliap rescriptiond rugc osts( Table1 ). Categorization of medicalservice claimsintooutpatient, hospital inpatient, ande mergency room wasb ased on placeo fs ervice codes. Totalcostsweredefined as thesum of theaforementioned costs.
Office visits were identified usingp lace of servicec ode1 1 (office).F or each cohort we computed them eann umbero f annualizedo fficev isits( categorizedb yp hysician specialty). Annualized office visits were computed as totalvisitsincurredby each patientd ivided by thet otal number of enrollmentm onths fort hatp atient,m ultipliedb y1 2. TheC harlsonC omorbidity Indexwas usedtoassess thecomorbidity of each cohort. 24 
StatisticalMethods
Statisticala nalysisw as performedu sing SAS9( SASI nstitute, Cary,NC).All statistical testswereperformed by comparingeach coinfected cohort (H + HCV, H + HIV, H + HIV + HCV) againstthe H-only group. Differencesinm eans were tested usingthe t test. TheMann-Whitney U test wasusedfor nonnormallydistributed data.Fisher'sexact test wasusedtotestthe statistical significance of differences forcategorical variables. Fisher's exacttestwas used insteado ft he Pearsonc hi-square test because of smallc ounts in some of thecells.
■■ Results
Demographic characteristics of thes tudy cohort ared isplayed in Table2.After all inclusionand exclusioncriteriawereapplied, 166p atientsw erei dentifiedf or thes tudy.H -onlyp atients accountedf or 44%o ft he patients (n =73),f ollowedb yp atients with H + HCV( 27%, n=44), H + HIV + HCV( 22%, n=37),a nd H + HIV( 7%,n=12).P atientsw ho hadH -onlyw ereo na verage 4t o6y ears youngert hanc oinfected hemophiliap atients.N o statisticallysignificantdifferencesinpayermix or mean number of months enrolled were noted. As expected,a ll 3c oinfected cohortsh ad significantlyh igherc omorbiditys corest hant he H-only cohort ( P < 0.001for H + HIVand H + HIV + HCV, P=0.001 forH+ HCV).
Annualized costsf or thec ohortsa re displayedi nT able 3. Then umbero fo fficev isitsb yg eneral practice ands pecialty type is showninT able 4. Theannualizedmeanofficevisitswere higher fort he H + HCV( 11.18, P=0.003) andH + HIV + HCV (18.33, P < 0.001) cohortst hanf or theH -onlyc ohort (6.98). Compared with theH -onlyc ohort,t he H + HIV + HCVc ohort hadag reater mean annualized number of visits to infectious diseases pecialists( 3.75 vs.0 .12, P < 0.001) andt og astroenterology specialists( 1.22 vs.0.09, P <0.001).
■■ Discussion
This studyf ound thatt he presence of virali nfectioni sa ssociated with significantlyi ncreased treatmentc ostsf or hemophilia patients in commercial health plans. Whilep reviouss tudies attempted to quantify thecost of hemophiliainthe United States, they didn ot report ther elatived ifference in costsa ttributedt o virali nfection. We foundt hatt otal mean annualized costsi n 2004 dollarsrangedfrom$90,942 forthe groupwithhemophilia only to $144,462 forhemophiliapatientswithbothHIV andHCV coinfection. Sincethisstudy wasconducted from theperspective of an insurer, thenet plan cost aftersubtraction of member costsharewas usedasthe measureofhealth care resource cost.
As mentionedp reviously,H eemstrae ta l. foundt he same pattern-thatc ostsi ncreased with more transmittedd iseases. 24 Differencesi no ur estimates arel ikelyb ecause Heemstra had estimated annual inflation-adjustedC anadianc ostsb etween 1978 and1 998f or ac ohort of 17 children in 1h ospitaland did notinclude non-hemophiliap rescriptiondrugcosts. Despitethe rarityo fh emophilia, evenaf ew patients can impose substantial costsonamanagedcareorganization.Viralcoinfectionsubstantiallyincreases that financial burden.
Hemophiliap atientswithH IV andH CV were more likely to have ag reater number of specialtyp hysician visits than were hemophiliacsw ithout similari nfection. Costsf or services providedwithaninpatient placeofstaywerealsosomewhat higher forpatientscoinfected with HIVand HCVthanfor patients with hemophiliaa lone.H owever, both studiesb yG lobe et al.a nd Minersetal. foundnostatisticallysignificant associationbetween occurrenceso fi npatient hospitalizationa nd HIVs tatusa fter adjustingfor severity of hemophilia. 15, 16 With currenttreatmentof HIVe ffectivelymakingi tac hronic condition, it is possible that Medical Costs andResource Utilization for HemophiliaPatientsWith andWithoutHI VorHCV Infection severity and agea re theb iggest predictors of hospitalizationi n coinfected hemophiliap atientsand attenuatethe impact of viral coinfection.
We foundthathemophiliapatientscoinfected with both HIV andHCV hadsignificantlyhigherclottingfactorutilization than didpatientswithhemophiliaonly. Otherstudies foundthatHIV status anddecreasingCD4+countsweresignificantlyassociated with increased clottingfactoruse. 17, 18, 24 Heemstra et al.f ound the weight-adjusted cost of factor VIII ranged from Can$1,000 perkg peryearfor severe hemophiliapatientswithnoviraltransmission to Can$2,206p er kg pery earf or severe patients with HIVa nd hepatitisBand/or C. 24 Severalo bservational studiesf ound that treatmento fH IV-positiveh emophiliap atientst reated with HIV protease inhibitors wasassociatedwithanincreased incidenceof bleeding episodes.W hile some individualsr eported an increase in frequency in bleeding in thesamesites as before HIVprotease inhibitortherapy wasinitiated,othersreportednew bleeds occurring at unusualsites,suchasthe smallj ointso fthe hand or the intraocularmuscles. [26] [27] [28] [29] HIVand HCVcoinfectioninpatientswithhemophiliaimposes al arge increase in non-hemophilicp rescriptiond rugc ost.T he introduction of highly active antiretroviralt herapy (HAART) significantlyr educed new AIDS cases, mortality,a nd opportunistici nfections in HIV-positive patients. 30, 31 AlthoughH AART substantiallydecreases inpatienthospitalization cost,itisaccompanied by significantlyh igherp harmacy, laboratory,a nd outpatientc aree xpenditures. 32 Purdum et al.e stimated that the drug costso fH IV-infected patients in am anaged care setting were approximately $15,768a nd accountedf or 78%o ft heir totalcosts. 33 Medical Costs andRe source Utilization for HemophiliaPatientsWith andWithoutHIV or HCVInfection estimated thesec ostsu sing averagew holesalep rice.W hile we didn ot explicitly look at thecomponento fdrugcostsrelated to HIVo rH CV,w ef ound thatm eana nnualizedn on-hemophilia prescription drugsc ostsf or theH + HIVa nd H + HIV + HCV groups were $8,239 and$ 12,360,approximately 4to5times the prescription drug costsofthe hemophilia-only group.
Drug costswerelikelyoverstatedbecause thestudy
In addition to having an economic impact,H IV or HCV infectionm ay also affect theh ealth-related qualityo fl ifeo f hemophiliacs; however, therei sc urrently no consensuso n whether viralinfectionhas anegativeimpact. Whilesomestudies reported thatH IV or hepatitis comorbidityc ausedasignificant decrease in HRQoLorhealth utility, [34] [35] [36] otherstudies didnot find anye ffect of HIVs tatus on HRQoL. 22, 37 Severalr easons fort his contradictionh ave been putf orward,i ncluding thep ossibility that (1)b ettert reatment hasr educed thei mpacto fH IV comorbidityo nH RQoL,( 2) thei nstruments usedt oa ssess quality of life(e.g.,Short Form 36,Health Utilities Index) aregeneral scales nots pecifict oh emophiliaa nd mayn ot be sufficiently sensitive to detect change in quality of lifef or ah emophiliap atient,o r (3)adaptationtothe health statemay have occurred. 38, 39 It is possiblethatthe marginal disutility of HIV, asecondchronic condition,o naf irst chronicc onditions ucha sh emophiliam ay have been small. Furtherresearchisrequired to resolvethisissue.
In theg eneral hemophiliap opulation, most hemophiliacs were infected with HIVa nd HCVt hrought he blood supply. 2, 3 Currentlya vailable hemophiliat herapies have varyingl evelso f exposure andv ulnerability to contaminationb yb lood-borne pathogens. 23 Whilet he threat of HIVo rH CV infectionh as been virtuallye liminated,e mergingp athogens such as variant Creutzfeldt-Jakobdisease pose arisktoblood-derived products. 23 This studyd emonstratesthe economic impact of HIVand HCV coinfectiononahemophiliapopulation.
Limitations
First, because of then atureo fc laimsd ata, we were unable to directly obtain severalclinicalmarkers thatare relevant to hemophilia, such as severity andt he development of inhibitors (antibodies to factor VIII). We identified inhibitorpatientsthroughthe use of recombinant factor VIIa or APCC andexcludedthemfrom thestudy.The presence of inhibitors hasbeenshown to dramaticallyincreasethe overalltreatment cost forhemophiliaand thus can confound therelationshipbetween viralinfectionstatusand resource use. 40, 41 Post hocanalysisofthe inhibitorpatients found that4o ft hese patients were in theh emophilia-only groupa nd 3w erei nt he HCVgroup,witham eanannualizedt otal cost of $635,296.H owever, this methodologym ay noth ave captured inhibitorcases treatedwithimmunetolerance inductiontherapy, whichusuallyinvolvesthe dailyinfusiono flarge doseso fFVIII over many months.
Second,there mayhave been under-reportingofHCV during thet imef rame of ours tudy.H CV antibodyt esting wasi ntroducedi n1 991a nd wasu nlikelyt oh ave been disseminated widely into practice by 1997.However, sincehemophiliapatients ares ignificantu sers of blood-derived products,t he hemophilia Fifth, this studyw as conductedu sing ar etrospectivec laims database analysis.Althoughsuchdatabases provideareasonably accurate estimate of direct medicalcosts, thereisapossibility of miscoding andm issing data.I no rder to guarda gainst possible diagnosisc odinge rrors, hemophiliap atientsw erei dentified as patients whoh ad at least1r ecordo fap rimary hemophilia diagnosisand at least1claim forahemophiliadrug.
Sixth, because we basedo ur medical servicec lassifications only on placeo fs ervice (e.g., without accountingf or revenue codesorother more specific data about serviceuse), it is possible thatc ostsw eremisclassified;h owever, ouranalyseso ft otal cost were unaffected by this problem. Arelated potentiallimitationis thec odingo fh emophilicfactorinthe hospital setting. It is possibleand even likelythatsomeclottingfactorcostswereassigned to thecategoryofinpatient hospital costs, potentiallybiasing factorcostsdownwardand inpatienthospitalization costsupward.
Seventh, althoughw eu sedad atabaseo fa pproximately 43 million lives, we identified only 166p atientsw ho mett he studycriteriaacrossthe 4study cohorts. On thebasis of national prevalence of 13.4 casesper 100,000 males, we wouldexpect to identify approximately2 ,880 patients versus the5 38 casest hat we identified before applying theexclusion criteria.Our requirement of at least1h emophiliadrugdispensationexcludedmany mild andmoderatehemophiliapatientsfromall cohorts. In addition,for thosemanaged care organizationsthatcontractout with as pecialty pharmacy to manage theiri njectable drugsb enefit, clottingf actora dministrative claimsd atam ay notb ea vailable fora nalysis. Thus,w ew ould have excluded theseh emophilia patients because theirFVIII claimsw eren ot accessible through either themanaged care organization or pharmacy benefitsmanager.Using allavailable diagnosispositions,not just theprimary diagnosis, wouldhave identified only 4morepatients.
Eighth,t he smalls amples izea nd high variability of health care costs, as reflected in high standard deviations,l imited the statisticalp ower of thed ataa nalysis. Thus,w ew ereu nable to detect anys tatistically significantd ifferencesi nt otal costs betweent he hemophiliam ono-infected cohorts( H + HCVa nd H + HIV) andt he hemophilia-only cohort,a lthoughw ed id find significantlyincreased non-hemophiliaprescriptiondrugcosts.
■■ Conclusion
Forp atientsw ithh emophilia, coinfectionw ithb othH IV and HCVi sa ssociatedw ithg reater totala nnualm edical costso f approximately 59%( 95%C I, 34.8%, 82.9%) in hemophiliacs. Coinfectionw ithH IV andH CV is associatedw iths ignificantly greaterc omponentc ostsf or clottingf actor, prescription drugs, inpatientservices, andoutpatientservices. 
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